Functional MRI for tumor delineation in prostate radiation therapy

Imaging in Medicine

Volumn 3, Issue 2, 2011, Pages 219-231

  Van Der Heide, Uulke A ^a   Korporaal, Johannes G ^a   Groenendaal, Greetje ^a   Franken, Stefan ^a   Van Vulpen, Marco ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

DCE MRI; diffusion weighted MRI; dose painting; dynamic contrast enhanced MRI; MRI; prostate; radiotherapy; tumor delineation

Indexed keywords

CANCER RADIOTHERAPY; CANCER STAGING; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; TUMOR LOCALIZATION;

EID: 79955123329     PISSN: 17555191     EISSN: 17555205     Source Type: Journal    
DOI: 10.2217/iim.11.10     Document Type: Review

References (86)

1. Pollack A, Zagars GK, Starkschall G et al.: Prostate cancer radiation dose response: results of the MD Anderson Phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097-1105 (2002). (Pubitemid 34787842)
2. Zietman AL, DeSilvio ML, Slater JD et al.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294, 1233-1239 (2005). (Pubitemid 41352111)
3. Peeters ST, Heemsbergen W, Koper PC et al.: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 24, 1990-1996 (2006). (Pubitemid 46622106)
4. Lips IM, Dehnad H, Van Gils CH, Boeken-Kruger AE, Van der Heide UA, Van Vulpen M: High dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verifcation: acute and late toxicity in 331 patients. Radiat. Oncol. 3, 15 (2008).
5. Lips IM, van Gils CH, van der Heide UA, Boeken Kruger UA, van Vulpen M: Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU Int. 103, 762-767 (2009).
6. Cellini N, Morganti AG, Mattiucci GC et al.: Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int. J. Radiat. Oncol. Biol. Phys. 53, 595-599 (2002). (Pubitemid 34626498)
7. Pucar D, Sella T, Schöder H et al.: The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr. Opin. Urol. 18, 87-97 (2008). (Pubitemid 350307537)
8. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M: Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared with seven field 3-dimensional radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 44, 921-929 (1999). (Pubitemid 29284143)
9. De Meerleer G, Villeirs G, Bral S et al.: The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother. Oncol. 75, 325-333 (2005) (Pubitemid 41007979)
10. Van Lin EN, Futterer JJ, Heijmink SW et al.: IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int. J. Radiat. Oncol. Biol. Phys. 65, 291-303 (2006).
11. Pinkawa M, Holy R, Piroth MD et al.: Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simulteneous integrated boost. Strahlenth. Onkol. 186, 600-606 (2010).
12. Bentzen SM: Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 6, 112-117 (2005). (Pubitemid 40197705)
13. Ennis RD: Potential benefits of intra-prostatic cancer-specific imaging to guide therapy and monitor outcome in patients treated with radiation-based treatments for localized prostate cancer. Cancer Biomark. 4, 197-199 (2008).
14. Fonteyne V, Villeirs G, Speleers B, et al.: Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int. J. Radiat. Oncol. Biol. Phys. 72, 799-807 (2008).
15. Singh AK, Guion P, Sears-Crouse N et al.: Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic leasions to 95 Gy with IMRT: early results of a phase I NCI study. Radiat. Oncol. 2, 36 (2007).
16. Trotti A, Byhardt R, Stez J et al.: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 47, 13-47 (2000). (Pubitemid 30179675)
17. Rasch C, Steenbakkers R, Van Herk M: Target definition in prostate, head, and neck. Semin. Radiat. Oncol. 15, 136-145 (2005). (Pubitemid 40835955)
18. McLaughlin PW, Troyer S, Berri S et al.: Functional anatomy of the prostate: implications for treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 63, 479-491 (2005). (Pubitemid 41317165)
19. Villeirs GM, Verstraete K, De Neve WJ, De Meerleer GO: Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother. Oncol. 76, 99-106 (2005). (Pubitemid 41096522)
20. Rosewall T, Kong V, Vesprini D et al.: Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses. Radiother. Oncol. 90, 325-330 (2009).
21. Hricak H, Choycke PL, Eberhardt SC, Leibel SA, Scardino PT: Imaging prostate cancer: a multidisciplinary perspective. Radiology 243, 28-53 (2007). (Pubitemid 46579693)
22. Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H: Prostate cancer imaging. Acta Radiol. 49, 107-120 (2008).
23. Seitz M, Shukla-Dave A, Bjartell A et al.: Functional magnetic resonance imaging in prostate cancer. Eur. Urol. 55, 801-814 (2009).
24. Kirkham AP, Emberten M, Allen C: How good is MRI at detecting and characterising cancer within the prostate? Eur. Urol. 50, 1163-1174 (2006).
25. Fütterer JJ, Heijmink SW, Scheenen TW et al.: Prostate cancer: local staging at 3-T endorectal MR imaging - early experience. Radiology 238, 184-191 (2006). (Pubitemid 43010595)
26. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62, 140-147 (2005). (Pubitemid 40096780)
27. Kim JK, Hong SS, Choi YJ et al.: Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J. Magn. Reson. Imaging 22, 639-646 (2005). (Pubitemid 41572716)
28. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 10, 223-232 (1999). (Pubitemid 29463104)
29. Fütterer JJ, Heijming SWTPJ, Scheenen TWJ et al.: Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241, 449-458 (2006). (Pubitemid 44632891)
30. Van Dorsten FA, Van der Graaf M, Engelbrecht MRW et al.: Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J. Magn. Reson. Imaging 20, 279-287 (2004). (Pubitemid 38970937)
31. Hom JJ, Coakley FV, Simko JP et al.: Prostate cancer: endorectal MR imaging and MR spectroscopic imaging - distinction of true-positive results from chance-detected lesions. Radiology 238, 192-199 (2006). (Pubitemid 43010596)
32. Shimofusa R, Fujimoto H, Akamata H et al.: Diffusion-weighted imaging of prostate cancer. J. Comput. Assist. Tomogr. 29, 149-153 (2005). (Pubitemid 40411296)
33. DeSouza NM, Reinsberg SA, Scurr ED, Brewster ED Payne GS: Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br. J. Radiol. 80, 90-95 (2007). (Pubitemid 46951251)
34. Morgan VA, Kyriazi S, Ashley SE, deSouza NM: Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. Acta. Radiol. 48, 695-703 (2007). (Pubitemid 47147765)
35. 2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 189, 323-328 (2007). (Pubitemid 47195916)
36. 2-weighted imaging. J. Magn. Reson. Imaging. 25, 146-152 (2007). (Pubitemid 46095209)
37. Yoshimitsu K, Kiyoshima K, Irie H et al.: Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J. Magn. Reson. Imaging. 27, 132-139 (2008).
38. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H: MR imaging of the prostate in clinical practice. MAGMA 21, 379-392 (2008).
39. 2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol. 49, 602-610 (2008).
40. Alonzi R, Padhani AR, Taylor NJ et al.: Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int. J. Radiat. Oncol. Biol. Phys. DOI:10.1016/j.ijrobp.2010.02.060 (2011) (Epub ahead of print).
41. Padhani AR, Hayes C, Landau S, Leach MO: Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed. 15, 143-153 (2002). (Pubitemid 34213404)
42. 1-weighted dynamic contrast-enhanced MRI. J. Magn Reson. Imaging 29, 641-648 (2009).
43. Parker GJ, Roberts C, Macdonald A, et al.: Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn. Reson. Med. 56, 993-1000 (2006). (Pubitemid 44691341)
44. 1-weighted MR imaging - initial experience. Radiology 233, 709-715 (2004).
45. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL: Combined diffusion-weighted and contrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology. J. Magn. Reson. Imaging 24, 108-113 (2006).
46. Ocak I, Bernardo M, Metzger G et al.: Dynamic contrast-enhanced MRI of prostate cancer at 3T: a study of pharmacokinetic parameters. Am. J. Roentgenol. 189, W192-W201 (2007).
47. Alonzi R, Taylor NJ, Stirling JJ et al.: Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J. Magn. Reson. Imaging 32, 155-164 (2010).
48. Groenendaal G, Van den Berg CAT, Korporaal JG et al.: Simulatenous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother. Oncol. 95, 185-190 (2010).
49. Kozlowski P, Chang SD, Meng R et al.: Combined prostate diffusion tensor imaging and dynamic contrast-enhanced MRI at 3T - quantitative correlation with biopsy. Magn. Reson. Imaging 28, 621-628 (2010).
50. 2, Ktrans, ve, and corresponding histologic features. Radiology 255, 485-494 (2010).
51. Henderson E, Milosevic MF, Haider MA, Yeung IWT: Functional CT imaging of prostate cancer. Phys. Med. Biol. 48, 3085-3100 (2003). (Pubitemid 37192922)
52. Jeukens CR, Van den Berg CA, Donker R et al.: Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multi-slice CT. Phys. Med. Biol. 51, 4329-4343 (2006). (Pubitemid 44261847)
53. Korporaal JG, van den Berg CAT, Jeukens CRLPN et al.: Dynamic contrast-enhanced CT for prostate cancer: relationship between image noise, voxel size, and repeatability. Radiology 256, 976-984 (2010).
54. Gibbs P, Pickles MD, Turnbull LW: Repeatability of echo-planar-based diffusion measurements of the human prostate at 3T. Magn. Reson. Imaging 25, 1423-1429 (2007). (Pubitemid 350122914)
55. Padhani AR, Liu G, Koh DM et al.: Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11, 102-125 (2009).
56. Scheenen TWJ, Heijmink SWTPJ, Roell SA et al.: Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 245, 507-516 (2007). (Pubitemid 47612533)
57. Heijmink SWTPJ, Fütterer JJ, Hambrock T et al.: Prostate cancer: body-array versus endorectal coil MR imaging at 3T - comparison of image quality, localization, and staging. Radiology 244, 184-195 (2007). (Pubitemid 46981973)
58. Heijmink SWTPJ, Scheenen TWJ, Van Lin ENJT et al.: Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. Int. J. Radiat. Oncol. Biol. Phys. 73, 1446-1453 (2009).
59. Kim Y, Hsu IC, Pouliot J, Noworolski SM, Vigneron DB, Kurhanewicz J: Expandable and rigid endorectal coils for prostate MRI: impact on prostate distortion and rigid image registration. Med. Phys. 32, 3569-3578 (2005).
60. Woel R, Beard C, Chen M-H et al.: Acute gastrointestinal, genetourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int. J. Radiat. Oncol. Biol. Phys. 62, 392-396 (2005). (Pubitemid 40704455)
61. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P: Detailed mapping of prostate carcinoma foci. Biopsy strategy implications. Cancer 89, 1800-1809 (2000).
62. Bott SRJ, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M: The index lesion and focal therapy: an analysis of pathologic characteristics of prostate cancer. BJU Int. 106, 1607-1611 (2010).
63. Schmuecking M, Boltze C, Geyer H et al.: Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer? Int. J. Radiat. Biol. 85, 814-824 (2009).
64. 2 - sparse versus dense cancers. Radiology 249, 900-908 (2008).
65. Haie-Meder C, Pötter R, Van Limbergen E et al.: Recommendations from gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother. Oncol. 74, 235-245 (2005). (Pubitemid 40349132)
66. Korporaal JG, Van den Berg CAT, Groenendaal G, Moman MR, Van Vulpen M, Van der Heide UA: The use of probability maps to deal with the uncertainties in prostate cancer delineation. Radiother. Oncol. 94, 168-172 (2010).
67. Shah V, Pohida T, Turkbey B et al.: A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev. Sci. Instrum. 80, 104301 (2009).
68. Turkbey B, Pinto PA, Mani H et al.: Prostate cancer: value of multiparametric MR imaging at 3T for detection - histopathologic correlation. Radiology 255, 89-99 (2010).
69. Park H, Piert MR, Khan A et al.: Registration methodology for histological sections and in-vivo imaging of human prostate. Acad. Radiol. 15, 1027-1039 (2008). (Pubitemid 351953912)
70. Groenendaal G, Moman MR, Korporaal JG et al.: Validation of functional imaging with pathology for tumor delineation in the prostate. Radiother. Oncol. 94, 145-150 (2010).
71. Vos PC, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, Barentsz JO, Huisman JJ: Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med. Phys. 35, 888-899 (2008). (Pubitemid 351322670)
72. 2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J. Magn. Reson. Imaging 30, 327-334 (2009).
73. Ozer S, Langer DL, Liu X et al.: Supervised and unsupervised methods for prostate cancer segmentation with multispectral MRI. Med. Phys. 37, 1873-1883 (2010).
74. Van Vulpen M, Van den Berg CAT, Moman MR, Van der Heide UA: Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiother. Oncol. 93, 180-184 (2009).
75. De Visschere PJ, De Meerleer GO, Fütterer JJ, Villeirs GM: Role of MRI in follow-up after focal therapy of prostate carcinoma. Am. J. Roentgenol. 194, 1427-1433 (2010).
76. Pucar D, Shukla-Dave A, Hricak H et al.: Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy - initial experience. Radiology 236, 545-553 (2005). (Pubitemid 41023438)
77. Westphalen AC, Coakley FV, Roach III M, McCulloch CE, Kurhanewicz J: Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 256, 485-492 (2010).
78. Rouviere O, Valette O, Grivolat S et al.: Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor - correlation with biopsy findings. Urology 63, 922-927 (2004). (Pubitemid 38596680)
79. Haider MA, Chung P, Sweet J et al.: Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70, 425-430 (2008).
80. Swanson MG, Vigneron DB, Tabatabai ZL et al.: Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 50, 944-954 (2003). (Pubitemid 37356574)
81. Zakian KL, Sircar K, Hricak et al.: Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234, 804-814 (2005). (Pubitemid 40250824)
82. Shukla-Dave A, Hricak H, Moskowitz C et al.: Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 245, 499-506 (2007). (Pubitemid 47612532)
83. Tamada T, Sone T, Jo Y et al.: Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J. Magn. Reson. Imaging 28, 720-726 (2008).
84. Yoshimitsu K, Kiyoshima K, Irie H et al.: Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J. Magn. Reson. Imaging 27, 132-139 (2008).
85. Hoskin PJ, Carnell DM, Taylor NJ et al.: Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry - initial observations. Int. J. Radiat. Oncol. Biol. Phys. 68, 1065-1071 (2007). (Pubitemid 47048571)
86. *) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int. J. Radiat. Biol. 85, 805-813 (2009).